Register for free and gain unlimited access to our extensive elearning library
Earn CME points and track your learning activity with hundreds of hours of continuing medical education.
Share :

Management of Radiopharmaceuticals in Older Patients

This module covers the SIOG guidelines for the management of radiopharmaceuticals in older patients. The information in this module is based on the position paper by Prior J et al. ‘Radiopharmaceuticals in the elderly cancer patient: practical considerations, with a focus of prostate cancer therapy - A proposition paper from a SIOG task force’.

Access the latest SIOG guidelines with our course on the management of multiple cancers in older patients.

Published May 2016. 

Management of Radiopharmaceuticals in Older Patients
0 CME Points

Target audience

This module is for medical practitioners who wish to gain knowledge on the SIOG recommended guidelines for the management of Radiopharmaceuticals in older patients.


Learning objectives

  • Enumerate most frequent cancers in the elderly population.
  • Understand general considerations regarding to age and frailty and their relation to radiopharmaceutical use.
  • Know the use of radiopharmaceuticals in elder patients for diagnosis.
  • Know and address concerns about using therapeutic radiopharmaceuticals risks for patients, family and care givers.
  • Know the place of radiopharmaceuticals among the therapeutic armamentarium in patients with prostate cancer.

IT Requirements

This module requires the learner to have a good, stable internet connection and runs best on INTERNET EXPLORER 7 AND ABOVE, and MOZILLA FIREFOX on either Windows or MacOS. FLASH ADD ON is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatability.

If you are experiencing technical difficulties, please contact and we will get back to you as soon as possible.

Disclosure policy

ecancer and Prof John O. Prior, Nuclear Medicine and Molecular Imaging Office, Rue du Bugnon, Lausanne, Switzerland have no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from Bayer.


Production of this module was funded by the International Society of Geriatric Oncology (SIOG) and by an unrestricted grant from Bayer.